Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (891-900 of 1,095) with videos related to

Pageof 110
Sort By:
Journal of Gastroenterology and Hepatology|July 8, 2026
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported OutcomesGeorge Papatheodoridis, Maria Buti, Yusuf Yilmaz, et al.
JHEP Reports : Innovation in Hepatology|May 27, 2021
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.
Journal of Clinical Gastroenterology|June 23, 2016
Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE StudySonia Rodríguez-Nóvoa, Javier García-Samaniego, Martín Prieto, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Pageof 110

Showing results (891-900 of 1,095) with videos related to

Sort By:
Pageof 110
Journal of Gastroenterology and Hepatology|July 8, 2026
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported OutcomesGeorge Papatheodoridis, Maria Buti, Yusuf Yilmaz, et al.
JHEP Reports : Innovation in Hepatology|May 27, 2021
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2020
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J Sonneveld, Jun Yong Park, Apichat Kaewdech, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.
Journal of Clinical Gastroenterology|June 23, 2016
Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE StudySonia Rodríguez-Nóvoa, Javier García-Samaniego, Martín Prieto, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Pageof 110